FIBER OPTIC FLUORESCENCE DETECTOR FOR PHOTOSENSITIZER

光敏剂光纤荧光检测器

• 批准号: 6513401
• 负责人: GREGORY C BURKE
• 金额: $ 34.88万
• 依托单位: AURORA OPTICS, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2004-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6513401
• 关键词: Animalia; biomedical equipment development; blood chemistry; clinical research; fiber optics; fluorescence; fluorescence spectrometry; human subject; photosensitizing agents; radiation detector; Animalia; biomedical equipment development; blood chemistry; clinical research; fiber optics; fluorescence; fluorescence spectrometry; human subject; photosensitizing agents; radiation detector

DESCRIPTION: The efficacy and safety of photodynamic therapy (PDT) depends on an understanding of photosensitizer and light biology and dosimetry. Therefore, the ability to accurately determine photosensitizer levels in tumors and at-risk normal tissues is of utmost importance. The goal of this work is to develop and test a prototype system for fluorescence based measurement of photosensitizer uptake in tissue, to improve photodynamic therapy (PDT) dosimetry. The fiber optic system is designed to quantify photosensitizer concentration by detecting a fluorescence intensity signal which minimizes the impact of the tissue optical properties. The bundle is also designed to maximize the signal intensity, allowing quantitation of low concentrations of photosensitizers. Specialized designs have been developed for tissue surface measurement, interstitial measurement and sampling of drawn blood samples. The system is flexible enough to measure either porphyrin-based or phthalocyanine-based photosensitizers, and will specifically be tested in aminolevulinic acid-induced protoporphyrin IX (ALA - PpIX), Photofrin and aluminum disuiphonated phthalocynanine. The system design will be tested in three specific applications where PDT can be successfully commercialized, including (i) veterinary animal tumor therapy, (ii) research in experimental animal tumors, and (iii) adjuvant therapy for human brain tumors after resection. In order to successfully evaluate the system in these different PDT markets, prototype systems will be developed and tested in academic research labs at Dartmouth Medical School and the University of Toronto. The tests will (i) determine how robust the design is, (ii) determine if this dosimetry method improves PDT treatment outcome and (iii) demonstrate safety in human use, prior to commercial development. PROPOSED COMMERCIAL APPLICATION: Not Available

描述：光动力疗法（PDT）的功效和安全性取决于 对光敏剂和光生物学和剂量法的理解。所以， 准确确定肿瘤中光敏剂水平的能力和 高危正常组织至关重要。这项工作的目的是 开发和测试原型系统，以基于荧光的测量 在组织中的光敏剂吸收，以改善光动力疗法（PDT） 剂量测定。光纤系统旨在量化光敏剂 通过检测荧光强度信号的浓度，该信号最小化 组织光学特性的影响。捆绑包也被设计为 最大化信号强度，可以定量低浓度 光敏剂。已经为组织表面开发了专业设计 抽血样品的测量，间质测量和抽样。这 系统足够灵活，可以测量基于卟啉或 基于邻苯胺的光敏剂，将在 氨基乙烯酸诱导的原源性IX（ALA -PPIX），光蛋白和 铝解析的邻苯胺。系统设计将在 PDT可以成功商业化的三个特定应用， 包括（i）兽医肿瘤疗法，（ii）实验研究 动物肿瘤和（iii）辅助治疗人类脑肿瘤 切除。为了成功评估这些不同的PDT中的系统 市场，原型系统将在学术研究中开发和测试 达特茅斯医学院和多伦多大学的实验室。测试将 （i）确定设计的鲁棒性，（ii）确定该剂量测定方法是否 改善PDT治疗结果和（iii）在人使用方面证明了安全性 进行商业发展。 拟议的商业应用： 无法使用